Certain Common Stock of Ikena Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-AUG-2023.
August 13, 2023
Share
Certain Common Stock of Ikena Oncology, Inc. are subject to a Lock-Up Agreement Ending on 14-AUG-2023. These Common Stock will be under lockup for 91 days starting from 15-MAY-2023 to 14-AUG-2023.
Details:
The officers, directors and certain other holders of outstanding capital stock have agreed, subject to specified exceptions, not to directly or indirectly sell, offer, contract or grant any option to sell pledge, transfer, establish an open ?put equivalent position? within the meaning of Rule 16a-l(h) under the Securities Exchange Act of 1934, as amended; otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially; or publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this prospectus without the prior written consent of certain of the representatives.
Ikena Oncology, Inc. is a targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company's lead targeted oncology program, IK-930, is a transcriptional enhanced associate domain 1 (TEAD1) selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company's second clinical-stage program targets the RAS signaling pathway with IK-595, a novel MEK-RAF molecular glue. It has IK-175 aryl hydrocarbon receptor (AHR) antagonist program that completed Phase 1 clinical trial. Its partnering portfolio also includes several other immune oncology programs that are available for potential sale or outlicensing, including PY314, a Phase 2 ready TREM2 antagonist, PY159, a Phase 2 ready TREM1 antagonist, and PY265, an IND-ready MARCO antagonist.